Literature DB >> 28344198

Radiosensitizing Effect of P2X7 Receptor Antagonist on Melanoma in Vitro and in Vivo.

Keisuke Tanamachi1,2, Keisuke Nishino1,2, Natsuki Mori1,2, Toshihiro Suzuki3, Sei-Ichi Tanuma2, Ryo Abe3, Mitsutoshi Tsukimoto1.   

Abstract

Melanoma is highly malignant, and generally exhibits radioresistance, responding poorly to radiation therapy. We previously reported that activation of P2X7, P2Y6, and P2Y12 receptors is involved in the DNA damage response after γ-irradiation of human lung adenocarcinoma A549 cells. However, it is not clear whether these receptors are also involved in the case of melanoma cells, although P2X7 receptor is highly expressed in various cancers, including melanoma. Here, we show that P2X7 receptor antagonist enhances radiation-induced cytotoxicity in B16 melanoma cells in vitro and in vivo. We confirmed that these cells express P2X7 receptor mRNA and exhibit P2X7 receptor-mediated activities, such as ATP-induced pore formation and cytotoxicity. We further examined the radiosensitizing effect of P2X7 receptor antagonist Brilliant Blue G (BBG) in vitro by colony formation assay of B16 cells. γ-Irradiation dose-dependently reduced cell survival, and pretreatment with BBG enhanced the radiation-induced cytotoxicity. BBG pretreatment also decreased the number of DNA repair foci in nuclei, supporting involvement of P2X7 receptor in the DNA damage response. Finally, we investigated the radiosensitizing effect of BBG on B16 melanoma cells inoculated into the hind footpad of C57BL/6 mice. Neither 1 Gy γ-irradiation alone nor BBG alone suppressed the increase of tumor volume, but the combination of irradiation and BBG significantly suppressed tumor growth. Our results suggest that P2X7 receptor antagonist BBG has a radiosensitizing effect in melanoma in vitro and in vivo. BBG, which is used as a food coloring agent, appears to be a promising candidate as a radiosensitizer.

Entities:  

Keywords:  DNA repair; P2X7 receptor; melanoma; radiosensitizer; γ-ray

Mesh:

Substances:

Year:  2017        PMID: 28344198     DOI: 10.1248/bpb.b17-00083

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

Review 1.  The P2 purinoceptors in prostate cancer.

Authors:  Zilin Wang; Sha Zhu; Sirui Tan; Yuhao Zeng; Hao Zeng
Journal:  Purinergic Signal       Date:  2022-06-30       Impact factor: 3.765

Review 2.  Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.

Authors:  Xuhui Bao; Liyi Xie
Journal:  J Exp Clin Cancer Res       Date:  2022-07-15

3.  Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling.

Authors:  Davide Ferrari; Stefania Gessi; Stefania Merighi; Manuela Nigro; Alessia Travagli; Jorge S Burns
Journal:  Front Cell Dev Biol       Date:  2022-05-04

Review 4.  Radiation-Induced Salivary Gland Dysfunction: Mechanisms, Therapeutics and Future Directions.

Authors:  Kimberly J Jasmer; Kristy E Gilman; Kevin Muñoz Forti; Gary A Weisman; Kirsten H Limesand
Journal:  J Clin Med       Date:  2020-12-18       Impact factor: 4.964

Review 5.  Membrane Transporters and Channels in Melanoma.

Authors:  Ines Böhme; Roland Schönherr; Jürgen Eberle; Anja Katrin Bosserhoff
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.